For this episode we will be reviewing three articles from the November-December 2021 issue of AllergyWatch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Moderators are Gerald Lee, MD; Stanley Fineman, MD; and Merin Kuruvilla Kalangara, MD.
Articles reviewed:
- Tezepelumab reduces exacerbations – even at lower eosinophil counts
Tezepelumab in adults and adolescents with severe, uncontrolled asthma. - Predicting response to aspirin therapy in NSAID-ERD
Biomarkers for predicting response to long-term high dose aspirin therapy in aspirin-exacerbated respiratory disease. - Can technology aid in asthma therapy adherence?
The impact of patient self-monitoring via electronic medication monitor and mobile app plus remote clinician feedback on adherence to inhaled corticosteroids: A randomized controlled trial.
Please rate our podcast on iTunes!
Please give us feedback, corrections and suggestions!
Email feedback to allergytalk@acaai.org
At the time of recording, the speakers had the following disclosures:
- Dr. Lee has nothing to disclose.
- Dr. Fineman: Speaker: Takeda; Research: Aimmune, DBV, BioCryst
- Dr. Kalangara: Speaker and Consultant: GlaxoSmithKline
Originally recorded February 23, 2022
Episode 29
ACAAI presents this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to the procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that may be referenced.
